Becton, Dickinson and Company (NYSE:BDX) authorized to pursue a plan to separate BD’s Biosciences and Diagnostic Solutions ...

Greg Rodetis; Senior Vice President, Treasurer and Head of Investor Relations; Becton Dickinson and Co Thomas Polen; Chairman of the Board, President, Chief Executive Officer; Becton Dickinson and Co ...

Becton Dickinson said it would focus on medtech and prioritize research, acquisitions and high-growth markets.

BDX's overall topline in the first quarter of fiscal 2025 continues to benefit from revenue growth in all segments.

Q1 2025 Management View Tom Polen emphasized several key updates, including the planned separation of BD’s Biosciences and Diagnostic Solutions businesses, which aims to create two strategically ...

(This Feb. 5 story has been refiled to correct the name of the unit to biosciences and diagnostic solutions, from life sciences, in the headline and paragraphs 1 and 4) (Reuters) - Becton Dickinson ...

Earnings Per Share (EPS) of $3.43, beating the estimated $3 and showing significant growth from the previous year’s $2.68. Revenue reached approximately $5.17 billion, surpassing the estimated $5.10 ...

License focused strategy delivered increased revenues and profitability Fourth quarter 2024 (October - December) Total revenue amounted to SEK ?68.3? (?61.3?) million, an increase of SEK ?6.9? million ...

Wells Fargo lowered the firm’s price target on Becton Dickinson (BDX) to $270 from $275 and keeps an Overweight rating on the shares. The firm ...

Piper Sandler analyst Jason Bednar maintained a Buy rating on Becton Dickinson (BDX – Research Report) today and set a price target of $280.00.

Becton Dickinson & Co. closed 9.83% short of its 52-week high of $251.99, which the company reached on February 3rd.

Becton Dickinson & Co. said it’s planning to separate part of its life sciences segment in a move aimed at raising the medical technology company’s stock.